Higher Irradiance in Keratoconus Ectasia

Not Applicable

Withdrawn

• Conditions: Ectasia; Keratoconus
• Interventions: Device: UVA Light with irradiance exposure of 9 mW/cm2; Drug: Riboflavin 0.1% ophthalmic solution

• Registration Number: NCT01789333
• Lead Sponsor: Stephen Trokel

Brief Summary

The purpose of the study is to see if brighter lights will allow for shortening of the treatment time required to stabilize the eyes of patients with keratoconus or a bulging cornea. The investigators will be comparing the therapeutic effects of two different higher brightnesses of ultra violet light on a riboflavin treated eye. One light will be twice as bright as the other and the exposure time of these brighter lights to deliver equivalent energy to the cornea will be reduced from the standard 30 minutes to 10 and 5 minutes. Riboflavin is vitamin B2 and the investigators are trying to determine if an identical clinical effect can be achieved the brighter treatment lights are used for shorter times. The investigators will also monitor the clinical effect and the status of the cornea to see if additional risks are associated with the brighter light.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-09-01
• Study First Submitted: 2012-11-20
• Study First Submitted QC: 2013-02-08
• Study First Posted: 2013-02-12
• Primary Completion: 2022-12-30
• Study Completion: 2022-12-30
• Status Verified: 2023-02
• Last Update Submitted: 2023-02-07
• Last Update Posted: 2023-02-09

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Subjects who have one or both eyes that meet two of the following criteria will be considered candidates for this study:

1. 16 years of age or older

2. Having a diagnosis of progressive keratoconus or pellucid marginal degeneration.

   1. Characteristic pattern of deformity as analyzed by the Pentacam map.
   2. Minimal thickness of 350 microns

3. The ability to sign a written informed consent

4. States a willingness and ability to comply with schedule for follow-up visits

5. Subject willing to remove contact lenses prior to evaluation and treatment

Inclusion criteria for ectasia

1. History of having undergone a keratorefractive procedure and show:

   1. Steepening by Pentacam study
   2. Thinning of cornea
   3. Shift in the position of thinnest portion of cornea
   4. Unstable refraction with increasing myopia and astigmatism
   5. Development of irregular astigmatism

2. At least two of the above criteria must be present.

Exclusion Criteria

Subjects meeting any of the following criteria will be excluded from this study:

Subjects meeting any of the following criteria will be excluded from this protocol:

1. Eyes classified as either normal or atypical normal,
2. Corneal pachymetry ≤ 350 microns at the thinnest point in treatment zone measured by Pentacam.
3. A history of delayed epithelial healing.
4. Pregnancy (including plan to become pregnant) or lactation during the course of the study
5. A known sensitivity to study medications
6. Patients with nystagmus or any other condition that is severe enough to prevent steady gaze during the treatment
7. Inability to cooperate with diagnostic tests.
8. Patients with a current condition that, in the investigator's opinion, would interfere with or prolong epithelial healing.
9. Patients who are unable to remain supine and tolerate a lid speculum.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
9 mw/cm2 at 10 minutes group	Riboflavin 0.1% ophthalmic solution	30 patients will be treated with UVA light source at 9 mw/cm2 at 10 minutes. Drug: Riboflavin Dose:1 drop every 2 to 3 minutes for 15 to 20 minutes
9 mw/cm2 at 10 minutes group	UVA Light with irradiance exposure of 9 mW/cm2	30 patients will be treated with UVA light source at 9 mw/cm2 at 10 minutes. Drug: Riboflavin Dose:1 drop every 2 to 3 minutes for 15 to 20 minutes

Primary Outcome Measures

Name	Time	Method
Change in Total Optical Aberrations of the Cornea following Cross-Linking	Baseline to 6 months	Assessment of changes in corneal curvature, as analyzed using a Pentacam Scheimpflug Analyzer will be used in all patients. This allows measurement of corneal thickness, maximum and minimum curvatures and aberration analysis of the cornea as an optical element. The most significant objective measure of change is the total Higher Order Aberrations of the cornea and the Kmax, or steepest curvature of the cornea. Analysis of corneal curvature is directly related to improvement in the corneal shape which is directly related to visual function.

Trial Locations

Locations (1)

Edward Harkness Eye Institute-Columbia University Medical Center; 🇺🇸 New York, New York, United States